As a new-type foreign trade service provider driven by technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory sources of CHP from multiple well-known brands.
As a foreign trade enterprise with R&D capabilities, HiSiaddi does not only promote its own brand like single-brand factories. We objectively analyze multiple well-known brands with high market share in China and globally, and share their major technological progress and breakthroughs, enabling purchasers to access more authentic, effective and up-to-date market information.
If you require more comprehensive and valuable CHP market information, please contact HiSiaddi customer service.
I. Core Breakthroughs and Indicator Improvements of Leading Domestic Brands (Mass Production Launched 2025–2026)
(I) High-Purity Refining Process Breakthrough: Limit Optimization of Single Impurity Indicators for Pharmaceutical & Electronic Grade CHP
New Kaiyuan and Hangzhou Lianyang jointly launched a coupled continuous rectification + molecular sieve deep adsorption new process for mass production. The purity of pharmaceutical & electronic grade CHP has been raised from 99.5% to 99.92%, single organic impurity content reduced from ≤0.2% to ≤0.03%, water content ≤50ppm, and all heavy metals lead/arsenic/cadmium <0.1ppm. This breaks the domestic ceiling for high-purity CHP impurity control and meets European EP Pharmacopoeia and US USP solvent access standards.
Downstream Benefits: Overseas API and photoresist cleaning purchasers eliminate the need for additional secondary rectification and purification, cutting single-ton raw material processing energy consumption by 18%; scrap rates of terminal pharmaceutical finished products caused by excessive solvent residues drop by 75%, and semiconductor electronic cleaning yield rises by 4%.
(II) Synthetic Route Improvement: Green Catalysis Waste Reduction & Sharp Production Cost Optimization
Puyang Kaisheng independently modified supported molecular sieve catalysts to replace traditional strong acid catalytic systems. CHP synthesis by-product yield fell from 11% to 2.7%, industrial three-waste emissions cut by 68%; comprehensive cyclohexylamine raw material conversion rate rose from 82% to 94.3%. After industrialization, factory delivery costs dropped by 12.5% year-on-year compared with 2024.
Downstream Benefits: Negotiated purchase prices for overseas coating and pesticide formulation purchasers fell by 8%–11% year-on-year; products comply with the latest EU REACH VOC control regulations, eliminating compliance rectification costs and shortening EU-wide customs clearance cycles by 3–5 working days.
(III) Low-VOC Modified Grade Mass Production: Launch of New Low-VOC Special CHP Grades
Dixin Chemical and Qilu Hengyuan developed modified low-VOC CHP grades with atmospheric boiling point increased by 12°C and saturated vapor pressure reduced by 62%. Adapted to European and American environmentally friendly water-based industrial coatings and eco-adhesive formulations, this new grade avoids excessive volatile emissions under high-temperature construction plaguing conventional CHP, and has obtained US EPA low-VOC solvent certification.
Downstream Benefits: European and American coating end factories can replace solvents without modifying existing production equipment, enabling finished product VOC indicators to easily meet California North American environmental regulations and expanding market access scope for end products.
II. Core Breakthroughs and Indicator Improvements of Leading Overseas Brands (Commercial New Products Launched 2025–2026)
(I) Ashland: New Heat Source-Free High-Purity CHP Exclusively for Pharmaceutical Auxiliaries, Innovation in Endotoxin Indicators
Launched sterile pharmaceutical-grade CHP new products in Q4 2025 with endotoxin <0.03EU/mg (conventional industry standard: 0.25EU/mg). Sterile filtration leaves no pyrogen residues, overcoming the industry-wide pain point of excessive pyrogens in injectable API synthesis solvents, exclusively adapted for injectable API synthesis scenarios.
Downstream Benefits: Global injectable pharmaceutical purchasers eliminate solvent depyrogenation processes, reducing production line investment in sterile supporting equipment and cutting quality control costs for terminal injectable drug production by 15%.
(II) BASF: Modified CHP Specialized for Lithium Battery Slurries, Upgraded Key Dissolution Stability Indicators
Optimized molecular modification formulations to prevent crystallization precipitation across a wide temperature range of -10°C~120°C. Dispersion uniformity of lithium battery positive electrode powder rises by 22%, residual solvent drying speed increases by 30%, exclusively designed for electrode slurry preparation in overseas power and energy storage batteries.
Downstream Benefits: Defect rates of electrode sheet pores and material shedding drop by 6% for European and American lithium battery manufacturers; energy consumption of electrode sheet drying sections falls by 22%, and long-term cycle stability of terminal power batteries sees mild improvement.
(III) DOW: Industrial Mass Production of Bio-Based Blended CHP, Breakthrough in Renewable Carbon Indicators
Achieved industrial mass production using bio-based cyclohexylamine as raw material, with finished product renewable carbon content ≥32% and carbon footprint reduced by 41% compared with petrochemical-based CHP. It has obtained EU ISCC sustainable raw material certification as the world’s first industrially mass-produced bio-based CHP grade.
Downstream Benefits: European and American end brands pursuing carbon neutrality (coatings, fine chemicals) can calculate product carbon emissions reduction after procurement, meeting EU CBAM carbon border adjustment mechanism accounting requirements and avoiding import carbon tariffs.
(IV) Eastman: Improved Low-Corrosion Special CHP, Optimized Equipment Loss Indicators
Adjusted polar group ratios to reduce corrosion rates on stainless steel/aluminum alloy equipment by 78%, adapted to precision electronic component cleaning and precision resin polymerization scenarios, solving the problem of production equipment corrosion from long-term immersion in conventional CHP.
Downstream Benefits: Maintenance cycles for overseas precision manufacturing purchasers extend from 3 months to 12 months, drastically cutting equipment maintenance expenses and raising yield of terminal precision components.
(V) Merck: Reagent-Grade Ultra-High-Purity CHP, Breakthrough in Chromatographic Residual Indicators
Reagent-grade products deliver no impurity peaks in gas chromatography with UV transmittance (254nm) ≥99.8%, breaking long-term monopolies of high-end chromatographic analysis solvents and adapted to laboratory pharmaceutical impurity analysis and precision chemical testing fields.
Downstream Benefits: Overseas third-party testing institutions and pharmaceutical R&D laboratories eliminate chromatographic baseline interference after procurement, reducing sample re-test rates by 40% and compressing terminal R&D testing costs.
III. General Industry-Wide Benefits from Shared Technological Breakthroughs Across All Product Categories
Accelerated domestic substitution of full high-purity specifications, with overseas purchasers seeing a 15%~22% drop in premium pricing for high-purity CHP compared with 2024.
Synchronously upgraded compliance of all product categories after green process implementation, enabling one-stop compliance with global REACH, EPA and FDA multi-region regulations; purchasers distributing across multiple countries avoid multi-batch qualification testing.
Full coverage of modified specialized grades (pharmaceutical/lithium battery/environmental coating dedicated), allowing purchasers to match multiple formulations with a single raw material and reduce multi-solvent inventory storage costs.
If you require more comprehensive and valuable CHP market information, please contact HiSiaddi customer service.